Despite advancements in new generations of biomaterials and medical devices, complications related to their use remain a burden for health care. In particular, healthcare-acquired infections (HAI) are a significant problem resulting in a variety of co-morbidities resulting in increased length of hospitalisation, antibiotic resistance and in more extreme cases, death.[1] Medical devices by their very nature are in contact with the body, whether that be the eye, internal tissues and/or bodily fluids such as blood and urine. The interface between the device and the biological environment is crucial and must fulfil a set of requirements to be biocompatible and safe. In particular, biofouling whereby host proteins can accumulate on the device/implant surface can result in a number of effects dependent on the site of the device/implant including thrombus formation, inflammatory responses and importantly bacterial infection leading to the aforementioned HAIs. While HAIs are largely treatable with antibiotic therapy, antibiotic resistance is a significant issue whereby the World Health Organisation (WHO) has developed a global action plan on antimicrobial resistance with a goal to reduce the incidence of infection through effective sanitation, hygiene and infection prevention measures.[2] One route towards achieving this goal is to improve our understanding of how bacteria interact with implant surfaces to develop biofilms, and thus armed with this knowledge work towards the development of preventative measures.